- All sections
- C - Chemistry; metallurgy
- C12N - Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media
- C12N 9/22 - Ribonucleases
Patent holdings for IPC class C12N 9/22
Total number of patents in this class: 10729
10-year publication summary
|
241
|
351
|
486
|
724
|
916
|
1165
|
1260
|
1396
|
1594
|
1163
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 19150 |
476 |
| The Broad Institute, Inc. | 1637 |
447 |
| President and Fellows of Harvard College | 5838 |
428 |
| Massachusetts Institute of Technology | 9834 |
415 |
| Sangamo Therapeutics, Inc. | 427 |
179 |
| Cellectis | 401 |
144 |
| Inscripta, Inc., FORMERLY Muse Biotechnology, Inc. | 301 |
143 |
| The General Hospital Corporation | 4572 |
136 |
| The Board of Trustees of the Leland Stanford Junior University | 6111 |
132 |
| CRISPR Therapeutics AG | 367 |
129 |
| Editas Medicine, Inc. | 233 |
127 |
| Arbor Biotechnologies Inc. | 150 |
123 |
| Pairwise Plants Services, Inc. | 197 |
107 |
| Pioneer Hi-Bred International, Inc. | 6311 |
106 |
| Beam Therapeutics Inc. | 190 |
103 |
| Novozymes A/S | 3331 |
101 |
| Precision Biosciences, Inc. | 170 |
96 |
| Regeneron Pharmaceuticals, Inc. | 3821 |
95 |
| Duke University | 2920 |
89 |
| University of Massachusetts | 2136 |
86 |
| Other owners | 7067 |